Eurofins Discovery

Eurofins Discovery can optimise your discovery process – whether you need complete, end-to-end services, help with one or more stages, or the products for discovery work.

With over 600 scientists around the world, 50 patents, and 30 billion data points screened, you can rely on Eurofins Discovery to provide you with the deep resources needed for your success.

Standalone Services. Offering the ability to support your projects on an as-needed basis across the drug discovery workflow, Eurofins Discovery offers you services for Medicinal Chemistry, Synthetic Chemistry, In Vitro Pharmacology, Safety & Efficacy, ADME & Toxicology, and Phenotypic Assays. In Vivo services are available through our partner lab, Pharmacology Discovery Services.

Integrated Drug Discovery. The DiscoveryOne™ integrated drug discovery team works hand-in-hand as partners with you, integrating all Eurofins Discovery capabilities to accelerate delivery of preclinical candidates by utilising our in-house project management and deep scientific expertise.

Products for Drug Discovery. Eurofins DiscoverX, a Eurofins Discovery company, is the trusted product solutions provider that can accelerate your programs with confidence with qualified reagents, cell lines, and assays ready to run today. Eurofins DiscoverX develops and manufactures cutting-edge assays, stable cell lines, membrane preps, enzymes, and reagents for drug discovery and development.

Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts

Whitepaper: Biomarkers and mechanisms of toxicity

Whitepaper: Profiling oncology candidates

Case study: Identifying allosteric modulators for GPCRs

Brochure: Custom Assay Development

Booklet: InCELL Pulse™ Target Engagement Kinase Reference Set

Application Note: An Easy-to-Use Assay to Measure Target Cell Death by Antibody Dependent Cellular Phagocytosis (ADCP)

Whitepaper: KINOMEscan® ELECT Kinase screening and profiling services

Whitepaper: InCELL target engagement assays

Whitepaper: Accelerating Biosimilar & Biobetter Drug Development: Ready-to-Use, Cell-Based Assays for Potency and Lot Release Testing

Whitepaper: BioSeek: Economic Impact of BioMAP® Profiling – Bridging the Gap from In Vitro to In Vivo

Human iPSC-derived cardiomyocytes for cardiac proarrhythmic risk assessment

Using bioactivity profiling to support the progression of phenotypic hits

Supporting the progression of phenotypic hits with bioactivity profiling

Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option

Drug Target Review – Issue #3 2017

Bioactivity profiling supporting the progression of phenotypic hits

Unprecedented fragment-based screening using Spectral Shift for GPCRs

Rapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies

CRISPR™ MDCKII cell lines development for bioavailability and DDI assessments

SAFIRE: AI predicted ADME for drug discovery: leveraging BioPrint

Biophysics in kinase drug discovery: FBS to PROTAC^® ternary complex characterisation

SH2 domains as a target class in cancer and inflammation

Cardiac and vascular safety liabilities using totality of evidence approach

Decoding cancer and inflammation: identifying selective inhibitors of SH2 domains

Comprehensive in vitro approach to evaluate transporter-mediated drug interactions in drug discovery

Leveraging the E3scan^TM technology platform for next-generation targeted protein degradation

Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes

Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes

Hit discovery for GPCRs: HTS or virtual screens?

Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform

Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement

Using bioactivity profiling to support the progression of phenotypic hits

Implementing ADCC assays in QC: When donor variability isn’t an option

Skin toxicity mechanisms associated with mGluR5 negative allosteric modulators

The mast cell receptor MrgX2 and drug-induced anaphylaxis